Contract Service Directory

Labomar Canada





Company Headquarters

50 Boulevard Hymus
Pointe-Claire, QC H9R 1C9
Canada

Contract Service Directory

    Related Content

    • Bio News | Biosimilars
      Know the Challenges of Biosimilar Manufacturing

      Know the Challenges of Biosimilar Manufacturing

      Best Practices for a Competitive Market
      Jerry Martin, Pharmaceutical and Life Sciences Consultant to PMMI, and, Dr. Michiel Ultee, Principal, Ulteemit BioConsulting, LLC 04.11.18

    • Breaking News | Drug Delivery | Industry News | Inspections
      Tapemark Passes Regulatory Hurdle

      Tapemark Passes Regulatory Hurdle

      Manufacturing facility completes successful FDA pre-approval and general GMP inspection
      06.07.17

    • Inspections | Regulatory Affairs

      Warning Letters & Close-out Letters

      Why does it take so long to get a close-out letter?
      06.06.17


    • Breaking News | Industry News | Inspections
      BioPharma Services Completes 3 FDA Inspections

      BioPharma Services Completes 3 FDA Inspections

      No Form 483’s reported
      06.05.17

    • Breaking News | Facilities | Industry News | Inspections
      Frontida BioPharm Launches Expansion Efforts

      Frontida BioPharm Launches Expansion Efforts

      Comes on heels of receiving FDA clearance
      05.26.17

    • Regulatory Affairs
      The FDA and Metrics

      The FDA and Metrics

      The Agency and industry continue to work together to achieve FDA’s objectives
      David Lonza, Lachman Consultant Services, Inc. 05.09.17


    • Breaking News | Clinical Trial Materials | Clinical Trials | Drug Development | Facilities | Industry News
      Carmell Therapeutics Expands Mfg. Capabilities

      Carmell Therapeutics Expands Mfg. Capabilities

      Will soon enter a Phase III study for its bone healing accelerant product
      05.09.17

    • Breaking News | cGMP Manufacture | Clinical Trial Materials | Fill/Finish | Industry News
      Dalton to Start GMP Mfg. for Inhalation Drug Candidate

      Dalton to Start GMP Mfg. for Inhalation Drug Candidate

      Arch Biopartners expects AB569 to enter phase I later this year
      05.05.17

    • Regulatory Affairs

      Establishments, Identifications, Submissions and Beyond

      A closer look at electronic submissions of manufacturing establishment information (MEI).
      Sharif Ahmed, Lachman Consultants 04.03.17


    • Trump Picks New FDA Commish

      Combatting high drug prices and overregulation likely to be high on agenda
      Tim Wright, Editor 04.03.17

    • Collaborations & Alliances | Drug Development | Drug Discovery | Preclinical Outsourcing

      Ligand Earns Janssen Milestone

      Files IND for an antibody discovered using Ligand’s OmniAb technology
      03.28.17

    • Breaking News | Industry News

      BioStem Expands Services

      Opens 503b pharmaceutical and stem cell research lab in Florida
      03.27.17


    • Capsules | Solid Dosage/Semi-solids

      Generic Drug Trends

      Industry faces tighter capacity, consolidation, and drug pricing uncertainty
      Edward S. Price, President, PCI 03.07.17

    • Regulatory Affairs

      Whither Washington?

      With a new administration, the future of the FDA may be the biggest wildcard in the outlook for CDMOs and their customers
      Gil Roth, President, Pharma & Biopharma Outsourcing Association 03.07.17

    • Regulatory Affairs

      Challenges and Advantages of International Regulatory Inspections

      A look at the processes and approaches followed by FDA
      Daniel Barreto, Lachman Consultants 03.07.17

    • Sharp celebrates International Women’s Day

      Sharp celebrates International Women’s Day

      At Sharp, we’re celebrating International Women’s Day.

    • Aseptic Processing | Bio News | Breaking News | Facilities | Fill/Finish | Industry News | Inspections | Lyophilization

      LSNE Completes Two FDA Inspections

      FDA PAI and general GMP inspection of two aseptic manufacturing plants and QC laboratory completed successfully
      03.06.17

    • QA/QC | Regulatory Affairs
      FDA’s Quality Agreements Guidance

      FDA’s Quality Agreements Guidance

      Evaluation of FDA’s recently issued Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry
      Paul Mason, Ph.D., Director of Lachman Consultant Services, Inc. 01.26.17